Dr Gareth Healey

Research Highlights

1. Healey, G. & Conlan, S. (2017). Therapeutic Development and the Evolution of Precision Medicine. Nanoscience and Nanotechnology for Human Health (pp. 359-378).

   SU Repository: https://cronfa.swan.ac.uk/Record/cronfa33096

   http://eu.wiley.com/WileyCDA/WileyTitle/productCd-3527338608.html
2. Howard, D., Garcia-Parra, J., Healey, G., Amakiri, C., Margarit, L., Francis, L., Gonzalez, D., Conlan, R., Conlan, S., & Garcia Parra, J. (2016). Antibody–drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. Interface Focus, 6(6), 20160054

   https://doi.org/10.1098/rsfs.2016.0054, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa33095
3. Vitorino Carvalho, A., Reinaud, P., Forde, N., Healey, G., Eozenou, C., Giraud-delville, C., Mansouri-Attia, N., Gall, L., Richard, C., Lonergan, P., Sheldon, I., Lea, R., Sandra, O., Healey, G., & Sheldon, M. (2014). SOCS genes expression during physiological and perturbed implantation in bovine endometrium. Reproduction

   https://doi.org/10.1530/rep-14-0214, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa18919
4. Vitorino Carvalho, A., Eozenou, C., Healey, G., Forde, N., Reinaud, P., Chebrout, M., Gall, L., Rodde, N., Padilla, A., Delville, C., Leveugle, M., Richard, C., Sheldon, I., Lonergan, P., Jolivet, G., Sandra, O., Healey, G., & Sheldon, M. (2014). Analysis of STAT1 expression and biological activity reveals interferon-tau-dependent STAT1-regulated SOCS genes in the bovine endometrium. Reproduction, Fertility and Development

   https://doi.org/10.1071/rd14034, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa18917
5. Healey, G., Zinnen, S., Lockridge, J., Richards, I., Evans, N., & Walker, W. (2010). Identification of small interfering RNA targeting Signal Transducer and Activator of Transcription 6: characterisation and selection of candidates for pre-clinical development. Journal of RNAi and Gene Silencing, 6(2), 401-410.

   SU Repository: https://cronfa.swan.ac.uk/Record/cronfa18794
6. Healey, G. (2006). Vaccine production and development: The challenges of realising a future free from disease. Microbiologist, 7(1), 28-30.

   SU Repository: https://cronfa.swan.ac.uk/Record/cronfa19234
7. Hill, J., Eyles, J., Elvin, S., Healey, G., Lukaszewski, R., Titball, R., & Healey, G. (2006). Administration of Antibody to the Lung Protects Mice against Pneumonic Plague. Infection and Immunity, 74(5), 3068-3070.

   https://doi.org/10.1128/IAI.74.5.3068-3070.2006, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa18788
8. Elvin, S., Healey, G., Westwood, A., Knight, S., Eyles, J., Williamson, E., & Healey, G. (2006). Protection against Heterologous Burkholderia pseudomallei Strains by Dendritic Cell Immunization. Infection and Immunity, 74(3), 1706-1711.

   https://doi.org/10.1128/IAI.74.3.1706-1711.2006, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa18787
9. Westwood, A., Elvin, S., Healey, G., Williamson, E., & Eyles, J. (2006). Immunological responses after immunisation of mice with microparticles containing antigen and single stranded RNA (polyuridylic acid). Vaccine, 24(11), 1736-1743.

   https://doi.org/10.1016/j.vaccine.2005.10.021, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa18786
10. Healey, G. (2005). Investigation of dendritic cells as a vector for vaccine delivery

    SU Repository: https://cronfa.swan.ac.uk/Record/cronfa19235

    http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.418466
11. Healey, G., Elvin, S., Morton, M., Williamson, E., & Healey, G. (2005). Humoral and Cell-Mediated Adaptive Immune Responses Are Required for Protection against Burkholderia pseudomallei Challenge and Bacterial Clearance Postinfection. Infection and Immunity, 73(9), 5945-5951.

    https://doi.org/10.1128/IAI.73.9.5945-5951.2005, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa18785
12. Westwood, A., Healey, G., Williamson, E., & Eyles, J. (2005). Activation of dendritic cells by microparticles containing Bacillus anthracis protective antigen. Vaccine, 23(29), 3857-3863.

    https://doi.org/10.1016/j.vaccine.2004.11.079, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa18784
13. Walker, W., Healey, G., Hopkin, J., Walker, W., & Healey, G. (2009). RNA interference of STAT6 rapidly attenuates ongoing interleukin-13-mediated events in lung epithelial cells. Immunology, 127, 256-266.

    https://doi.org/10.1111/j.1365-2567.2008.02951.x, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa10002
14. Borges, Á., Healey, G., Sheldon, I., & Sheldon, M. (2012). Explants of Intact Endometrium to Model Bovine Innate Immunity and Inflammation Ex Vivo. American Journal of Reproductive Immunology, 67(6), 526-539.

    https://doi.org/10.1111/j.1600-0897.2012.01106.x, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa11549
15. Turner, M., Healey, G., Sheldon, I., Healey, G., Sheldon, M., & Turner, M. (2012). Immunity and Inflammation in the Uterus. Reproduction in Domestic Animals, 47, 402-409.

    https://doi.org/10.1111/j.1439-0531.2012.02104.x, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa13924
16. Healey, G., Evans, N., Hopkin, J., Davies, G., & Walker, W. (2013). Evaluation of nasal epithelium sampling as a tool in the preclinical development of siRNA-based therapeutics for asthma. Journal of Cellular and Molecular Medicine, 17(3), 356-364.

    https://doi.org/10.1111/jcmm.12014, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa17098
17. Walker, W. & Healey, G. (2014). Development of Pre-Clinical Models for Evaluating the Therapeutic Potential of Candidate siRNA Targeting STAT6. PLoS ONE, 9(2), e90338

    https://doi.org/10.1371/journal.pone.0090338, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa17428

    http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0090338
18. Turner, M., Cronin, J., Healey, G., Sheldon, I., & Sheldon, M. (2014). Epithelial and Stromal Cells of Bovine Endometrium Have Roles in Innate Immunity and Initiate Inflammatory Responses to Bacterial Lipopeptides In Vitro via Toll-Like Receptors TLR2, TLR1, and TLR6. Endocrinology, 155(4), 1453-1465.

    https://doi.org/10.1210/en.2013-1822, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa17657

    http://press.endocrine.org/doi/pdf/10.1210/en.2013-1822
19. Amos, M., Healey, G., Goldstone, R., Mahan, S., Düvel, A., Schuberth, H., Sandra, O., Zieger, P., Dieuzy-Labaye, I., Smith, D., Sheldon, I., & Sheldon, M. (2014). Differential Endometrial Cell Sensitivity to a Cholesterol-Dependent Cytolysin Links Trueperella pyogenes to Uterine Disease in Cattle1. Biology of Reproduction, 90(3)

    https://doi.org/10.1095/biolreprod.113.115972, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa17658
20. Sheldon, I., Cronin, J., Healey, G., Gabler, C., Heuwieser, W., Streyl, D., Bromfield, J., Miyamoto, A., Fergani, C., Dobson, H., Cronin, J., Healey, G., & Sheldon, M. (2014). Innate immunity and inflammation of the bovine female reproductive tract in health and disease. Reproduction, 148(3), R41-R51.

    https://doi.org/10.1530/REP-14-0163, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa18387
21. Saut, J., Healey, G., Borges, A., Sheldon, I., Healey, G., & Sheldon, M. (2014). Ovarian steroids do not affect bovine endometrial cytokine or chemokine responses to Escherichia coli or LPS in vitro. Reproduction, 148(6), 593-606.

    https://doi.org/10.1530/REP-14-0230, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa19256
22. Healey, G., Collier, C., Griffin, S., Schuberth, H., Sandra, O., Smith, D., Mahan, S., Dieuzy-Labaye, I., & Sheldon, M. (2016). Mevalonate Biosynthesis Intermediates Are Key Regulators of Innate Immunity in Bovine Endometritis. The Journal of Immunology, 196(2), 823-831.

    https://doi.org/10.4049/jimmunol.1501080, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa25016
23. Healey, G., Conlan, S., & Conlan, S. (2017). Nanoscience and Nanotechnology for Human Health. Nanoscience and Nanotechnology for Human Health (pp. 359-374). Wiley

    SU Repository: https://cronfa.swan.ac.uk/Record/cronfa31652

    http://eu.wiley.com/WileyCDA/WileyTitle/productCd-3527338608.html
24. Lesage-Padilla, A., Forde, N., Poirée, M., Healey, G., Giraud-Delville, C., Reinaud, P., Eozenou, C., Carvalho, A., Galio, L., Raliou, M., Oudin, J., Richard, C., Sheldon, I., Charpigny, G., Lonergan, P., Sandra, O., & Sheldon, M. (2017). Maternal metabolism affects endometrial expression of oxidative stress and FOXL2 genes in cattle. PLOS ONE, 12(12), e0189942

    https://doi.org/10.1371/journal.pone.0189942, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa37796
25. Griffin, S., Healey, G., Sheldon, I., & Sheldon, M. (2018). Isoprenoids increase bovine endometrial stromal cell tolerance to the cholesterol-dependent cytolysin from Trueperella pyogenes†. Biology of Reproduction, 99(4), 749-760.

    https://doi.org/10.1093/biolre/ioy099, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa39610
26. Healey, G., Frostell, A., Fagge, T., Gonzalez, D., Conlan, R., & Conlan, S. (2019). A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development. Antibodies, 8(1), 7

    https://doi.org/10.3390/antib8010007, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa48095
27. Pisano, S., Giustiniani, M., Francis, L., Gonzalez, D., Margarit, L., Sheldon, M., Paolino, D., Fresta, M., Sawhney, A., & Healey, G. (2019). Liquid crystal delivery of ciprofloxacin to treat infections of the female reproductive tract. Biomedical Microdevices, 21(2)

    https://doi.org/10.1007/s10544-019-0385-x, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa49813
28. Carvalho, A., Eozenou, C., Richard, C., Forde, N., Healey, G., Giraud-Delville, C., Mansouri-Attia, N., Lonergan, P., Sheldon, I., Sandra, O., Healey, G., & Sheldon, M. (2019). Bovine scavenger receptor class A (SR-A) exhibit specific patterns of regulation in the endometrium during the oestrous cycle and early pregnancy. Reproduction, Fertility and Development

    https://doi.org/10.1071/RD18411, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa49879
29. Healey, G., Pan Castillo, B., Garcia Parra, J., Davies, J., Roberts, S., Jones, E., Dhar, K., Nandanan, S., Tofazzal, N., Piggott, L., Clarkson, R., Seaton, G., Frostell, A., Fagge, T., McKee, C., Margarit, L., Conlan, S., & Gonzalez, D. (2019). Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer. Journal for ImmunoTherapy of Cancer, 7(1)

    https://doi.org/10.1186/s40425-019-0765-z, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa52619
30. Eozenou, C., Lesage-Padilla, A., Mauffré, V., Healey, G., Camous, S., Bolifraud, P., Giraud-Delville, C., Vaiman, D., Shimizu, T., Miyamoto, A., Sheldon, M., Constant, F., Pannetier, M., & Sandra, O. (2020). FOXL2 is a Progesterone Target Gene in the Endometrium of Ruminants. International Journal of Molecular Sciences, 21(4), 1478

    https://doi.org/10.3390/ijms21041478, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa53643

All Research

• Factors Influencing Open Innovation and Resilience of Small-to-Medium Enterprises in the United Kingdom’s Life Science Sector (current)

  PhD

  Other supervisor: Dr Simon Brooks

• PM-344 Capstone Project

  The aim of this module is to provide a capstone experience to students¿ learning, through participating in their own enquiry-based research project. The project may be laboratory or non-laboratory based, but it will always involve a research question that is drawn from the literature, and focused on a topic relevant to medical science. It will ask a novel research question and involve the critical analysis of research findings. Students will refine their oral and written communication skills to a graduate level through creating an introductory presentation on the project background, and a written dissertation and oral presentation on their research conclusions.

• PM-355 Drug Development and Regulation

  This is an applications and project management driven module designed to provide the student with an introduction to drug development and the key role of separation science and mass spectrometry within the pharmaceutical industry. This module will introduce Good Laboratory, Clinical and Manufacturing Practice (GLP, GCP, GMP), assay validation (as requested by the Food and Drug Administration (FDA)), the need and implementation of SOPs with particular focus on the pharmaceutical and medical industries, and how these correlate with stringent quality control procedures and health and safety existing due to current legislation. The ethical principles of research, including clinical trials and animal research (design, implementation and reporting) will be outlined, as well as the essential nature of the principles of reduction, refinement and replacement for the use of animals in research. Students will also be able to characterize and map the path of a drug from administration, to metabolism and elimination, for critical evaluation of drug design.

• PMC100 Chemistry for Biochemists

  The module covers transition metals, elements of bio-inorganic chemistry, forensic chemistry, antibody-drug conjugate chemistry, the chemistry of nanoparticles and the chemistry of biosensors.

• PMNM11 Nanomedicines, pharmaceuticals and advanced therapeutics

  This module will explore the history and development of molecular medicines and pharmaceuticals, providing the basis for an advanced understanding of next generation therapeutic approaches. Using landmark technology and chemical development phases informed by separation science and mass spectrometry, the module uses an application driven approach to provide the student with an extensive knowledgebase of drug development, the pharmaceutical industry and nanotherapeutics. Students will be able to characterize and map the path of a drug from administration, to metabolism and elimination, and critically evaluate drug design and delivery approaches. Traditional small chemical entities used in molecular medicine will be outlined, using drugs such as taxols and tamoxifen as exemplars. Common target oncology and non-oncology disorders will provide the context; with students encouraged to explore targeted nanoparticle fabrication, drug encapsulation and release profiling, from early first generation drugs such as Abraxane to second generation biologically targeted SMART delivery systems. Future molecular medicines such as antibody drug conjugates and kinase inhibitors will be taught by guest lectures from industry and clinicians, covering the spectrum of drug development to delivery and clinical considerations.

• PMNM12 Research Innovation and Management

  The growth of the personalised medicine industry and advances within medicine and engineering that have led to the emergence of nanomedicine, present exciting opportunities for the development of advanced therapeutics. However, the management of research and innovation from discovery through to the transition to clinical trial, present unique project management, regulatory and ethical challenges that must be considered to effectively develop new diagnostics and therapeutics. This module will take students through the development process for a novel nanomedicine, highlighting the project management, ethical and regulatory considerations at each stage. The module will also explore the challenges faced from an academic and industry perspective, as well as providing the opportunity for students to learn from industry leaders with direct experience of the research and innovation journey.

• Celtic Advanced Life Science Innovation Network (CALIN) 2016 - 2023

  , €19M

• Medical Research Council - Confidence in Concept 2020

  , £149K

• Senior Lecturer, Swansea University Medical School

  2019 - Present

• Project Manager – Celtic Advanced Life Science Innovation Networ, Swansea University Medical School

  2016 - Present

• Senior Research Officer – Reproductive Biology and Gynaecologica, Swansea University Medical School

  2014 - Present

• BBSRC Postdoctoral Research Scientist – Centre for Reproductive , Swansea University Medical School

  2011 - Present

• Senior Scientist – Allerna Therapeutics Ltd. , Swansea University Medical School

  2008 - Present

• Research Associate – Experimental Medicine Unit , Swansea University Medical School

  2007 - Present

• Research Scientist , Defence Science and Technology Laboratory (Dstl)

  2001 - Present